SAN ANTONIO, October 22, 2018 -- The first report of a large international clinical trial shows that, for men who show signs of prostate cancer after surgical removal of their prostates, extending radiation therapy to the pelvic lymph nodes combined with adding short-term hormone therapy to standard treatment can extend the amount of time before their cancer spreads. The findings, presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO), were so encouraging --exceeding rigorous threshold criteria -- that the results were released by the research team ahead of schedule.
Men with prostate cancer who are initially treated with prostatectomy -- surgical removal of the prostate gland -- often face signs of recurrence, usually signaled by a rise in the level of prostate specific antigen (PSA) in the blood. Radiation therapy to the region of the prior prostate surgery (surgical bed) is standard but only effective at keeping PSA low longer than five or more years in 60 to 70 percent of patients, said the study's lead author, Alan Pollack, MD, PhD, Chair of radiation oncology at the University of Miami and deputy director of the Sylvester Comprehensive Cancer Center.
While a rise in PSA after prostatectomy signals that the cancer is still present, it does not indicate where the cancer is located. The NRG Oncology/RTOG 0534 SPORRT clinical trial is the first randomized trial to show that radiation therapy to treat the pelvic lymph nodes in addition to standard prostate bed results in significant incremental gains for these patients.
"We looked specifically at men with prostate cancer who began to show signs that the cancer was not completely eradicated after prostatectomy," said Dr. Pollack. "Adding hormone therapy and pelvic lymph node treatment substantively increased the proportion of patients who remained free from disease progression, to the point that we could report the data after an early interim analysis. The degree of the effectiveness of the combination is surprising, but makes sense when you consider other more contemporary evidence using newer PET scanning methods showing that pelvic lymph node recurrences are more common than previously appreciated."
The SPPORT trial enrolled 1,792 men at centers in the U.S., Canada and Israel from 2008 to 2015. Eligible patients had persistently detectable or rising PSA levels and evidence that some cancer cells were left behind after prostatectomy in the prostate bed, pelvic lymph nodes or elsewhere in the body after prostatectomy. The median patient age was 64 years (range 39-84), most patients (87 percent) were Caucasian, and the men had generally favorable performance status.
Patients in the SPPORT trial were randomly placed into three treatment groups: prostate bed radiation therapy (PBRT) alone, PBRT plus short-term androgen deprivation (hormone) therapy (STAD), and PBRT plus pelvic lymph node radiotherapy (PLNRT) plus STAD. Hormone therapy consisted of four-to-six months of androgen deprivation to reduce levels of testosterone, a driver of prostate cancer.
The trial was designed to assess freedom from disease progression at five years following treatment. Findings from a scheduled interim analysis when 1,191 patients had been followed for five years triggered the early release of the findings, explained Dr. Pollack. "The level of significance reached at this point was considerable, making it unlikely that the results will change substantively with longer follow-up, although outcomes such as the rates of distant metastasis and survival require much more patient follow-up, " he said. "Releasing the data at this juncture is important for physicians treating patients with a rising PSA following prostatectomy. The strategy of combining prostate bed and pelvic lymph node radiation therapy with short-term hormone therapy should be much more strongly considered in routine clinical practice than it is currently."
At five years following treatment, freedom-from-progression (FFP) rates in the interim analysis group were 71.7 percent for PBRT alone, 82.7 percent for PBRT+ADT and 89.1 percent for PLNRT+PBRT+ADT. The FFP rate was highest for the arm combining all three treatments (p<0.0001). Freedom from progression was defined as a PSA nadir of +2, clinical failure or death from any cause.
Rates of cancer spread were also significantly different between treatment arms. In all eligible patients followed for up to eight years, distant metastases were found in 45 patients in the PBRT-only arm, 38 patients in the PBRT+ADT arm and 25 patients in the PLNRT+PBRT+ADT arm. Distant metastasis rates were significantly lower following the three-treatment approach compared to PBRT alone (Hazard Ratio 0.52, 95% CI: 0.32-0.85) and compared to PBRT+ADT (HR 0.64, 95% CI: 0.39-1.06).
"While it is common practice to treat the lymph nodes in men with higher-risk prostate cancer treated without prostatectomy first), this study is the most convincing level-I evidence to demonstrate a benefit," noted Dr. Pollack. "To be seeing differences in distant metastasis with relatively short follow-up speaks to the robustness of the impact, suggesting that the results will be sustained with longer follow-up."
Another key finding of the SPPORT trial is that short term hormone therapy (also called androgen deprivation therapy or ADT) is a key component of the management of patients with signs of recurrence after prostatectomy. SPPORT is only the second trial to look specifically at adding short-term hormone therapy to radiation for men following prostatectomy, added Dr. Pollack. "There are a lot of data showing a benefit from adding short-term hormone therapy in men whose prostate hasn't been removed, though only one other randomized trial -- GETUG 16 -- has shown significant improvements after prostatectomy. Our study confirms that adding STAD to PBRT following surgery extends the time to progression."
Rates of severe side effects (grade three or higher using CTCAEv3.0) were low across treatment groups. During treatment, the main additional severe effects from PLNRT were in relation to blood/bone marrow events. For long-term effects, blood/bone marrow events were also slightly higher in the PLNRT arm, but only for grade 2+ events (4.1 percent), not grade 3+ (1.1 percent).
Additional analyses of the SPPORT trial will focus on the magnitude of difference between the experimental treatment arms to isolate the impact of pelvic lymph node treatment relative to androgen deprivation therapy. The research team also described preliminary data that for those with a very low PSA on study entry, there was no improvement from PLNRT+PBRT+STAD over PBRT+STAD; although, this was an unplanned analysis.
"It's now a question of management, of whether a PSA threshold or other factors can be used to identify a patient group in which pelvic lymph node treatment is not as beneficial," concluded Dr. Pollack. "Moreover, the role of newer PET tracers that identify pelvic lymph node involvement earlier in this decision process remains a key question. We still need more data, but we've taken a significant step forward with this study."
The abstract, "Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiation therapy: The NRG Oncology/RTOG 0534 SPPORT trial," will be presented in detail during a news briefing and an oral abstract session at ASTRO's 60th Annual Meeting in San Antonio. To schedule an interview with Dr. Pollack and/or outside experts in prostate cancer, contact ASTRO's media relations team on-site at the Henry B. González Convention Center October 21 through 24, by phone at 703-286-1600 or by email at press@astro.org.
###
Attribution to the American Society for Radiation Oncology (ASTRO) Annual Meeting requested in all coverage.
This news release contains additional and/or updated information from the study author(s).
Study Presentation Details
- News Briefing: Monday, October 22, 11:00 a.m. - 12:00 p.m. CT, Room 225-D, http://bit.ly/ASTRO18-2
- Scientific Session: Monday, October 22, 2:15 - 3:45 p.m. CT, Stars at Night Ballroom
- Abstract available on the final page of this release.
ABOUT ASTRO
The American Society for Radiation Oncology (ASTRO) is the world's largest radiation oncology society, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. The Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology * Biology * Physics, Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, RT Answers; and created the nonprofit foundation Radiation Oncology Institute. To learn more about ASTRO, visit astro.org or RTanswers.org, sign up to receive our news and follow us on our blog, Facebook and Twitter.